Nucana shares rise 10.45% intraday on improved Q3 2025 financials, reduced net loss, and extended cash runway into 2029.

NuCana surged 10.45% intraday trading as improved financials and extended liquidity fueled investor optimism. The biopharmaceutical firm reported a sharply reduced third-quarter net loss of £0.3 million compared to £4.5 million in 2024, while liquidity rose to £25.2 million via an ATM offering. Management now projects sufficient cash to fund operations through 2029, alleviating near-term liquidity concerns and signaling stronger financial stability. These developments, combined with ongoing clinical progress, offset prior market pressures, driving a sharp intraday rebound.